The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

A meta-analysis of recent studies found a global steatotic liver disease prevalence of 37.5%. ( Clinical Gastroenterology and ...

Subjects with locally advanced or metastatic solid tumours, including high-grade serious ovarian cancer, are being enrolled ...

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today that its comprehensive genomic profiling assay Northstar ...

Prevent Cancer Foundation's 2025 Early Detection Survey showed that only about half of U.S. adults 21 years and older said ...

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on genetic mutations.

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...

“In this study of routine clinical practice data from US oncology practices, patients with MSI-H [microsatellite instability–high] [metastatic] CRC who received ICIs in an early line of ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

The Food and Drug Administration announced it has approved nivolumab, or Opdivo, marketed by Bristol Myers (BMY) Squibb, with ipilimumab, or ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...